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Background
During the course of HIV-1 infection, the status of
immune activation is associated with disease progression.
The immune system has adopted self-regulatory mecha-
nisms to counterbalance undesirable immune activation.
Regulatory T cells (TReg) expressing FoxP3 and CD4+ T
cells expressing IL-17 (TH17) play an important role in
this phenomenon. We hypothesized that a have couter-
balance of TH17 and TReg cells is found in subjects pro-
gressing to immunodeficiency.
Methods
Twenty-six individuals HIV-1-infected subjects were ana-
lysed pre and post antiretroviral treatment. PBMC were
stained and run using a 6-color flow cytometer to evaluate
immunophenotyping of forkhead box P3 (Foxp3), and
the activation status. PBMC with or without phorbol myr-
istate acetate (PMA) and ionomycin stimulation were
evaluated using a combination of markers (CD4, CD3, IL-
17, IL-2, TNF-α and IFN-).
Results
Data points were compared using non-parametric meth-
ods. The pre-treatment sampes tended to have lower
TRegs and TH17 cells compared to post-treatment sam-
ples. Pre- and post-treatment T cell activation levels, as
measured by the expression of HLADR+CD38+CD69+ on
CD4+ T cells (2.5 [1.6 – 3.4] vs. 1.4 [0.8 – 1.7], respec-
tively, p < 0.01) and CD38+HLADR+ on CD8+ T cells
(42.90 [31.35 – 50.75] vs. 17.50 [8.65 – 23.95], respec-
tively, p < 0.0001) cells was higher in pre-treatment sam-
ples. The levels of CD4+ T cell activation, measured by
CD69 expression, was positively associated with the fre-
quency of TH17 cells (r = 0.72, p < 0.001), but negatively
associated with the frequency of TRegs (r = -0.53, p <
0.05), both measured in the pre-treatment, which was lost
after the initiation of antiretroviral drugs.
Conclusion
TRegs and TH17 cells have opposite effects on T cell acti-
vation in HIV-infected subjects who are progressing to
immunodeficiency, but this counterbalance is overshad-
owed by the initiation of antiretroviral therapy. These
results suggest that the intense activation seen with the
progression to immunodeficiency is largely reflected in
the peripheral blood of such patients.
from AIDS Vaccine 2009
Paris, France. 19–22 October 2009
Published: 22 October 2009
Retrovirology 2009, 6(Suppl 3):P3 doi:10.1186/1742-4690-6-S3-P3
<supplement> <title> <p>AIDS Vaccine 2009</p> </title> <editor>Anna Laura Ross</editor> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1742-4690-6-S3-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1471-2105-10-S12-info.pdf</url> </supplement>
This abstract is available from: http://www.retrovirology.com/content/6/S3/P3
© 2009 Carvalho et al; licensee BioMed Central Ltd. 